TLDR
- TRIB soars 51% after a 9M TrinScreen HIV order boosts growth and revenue.
- Trinity Biotech strengthens global HIV diagnostics with massive test order.
- TRIB stock surges on high demand for TrinScreen HIV screening tests.
- Q3 revenue rises 32% as TrinScreen HIV sales rebound strongly.
- WHO-approved manufacturing helps TRIB scale HIV test production efficiently.
Trinity Biotech plc (TRIB) stock surged dramatically to $1.3502, reflecting a 51% intraday gain.
Trinity Biotech plc, TRIB
The rise followed a significant order for 9 million units of TrinScreen HIV. This surge highlights strong demand for the company’s HIV screening products in global markets.
TrinScreen HIV Order Boosts Market Presence
TRIB received the order amid renewed global efforts to expand HIV testing programs. The company will produce TrinScreen HIV through WHO-approved outsourced manufacturing. Production can scale efficiently to meet rising demand in high-need regions.
The order represents a critical milestone for TRIB in restoring global health market stability. TrinScreen HIV is a rapid diagnostic test prequalified by WHO for large-scale screening. The product’s design ensures reliable results and ease of use in diverse clinical settings.
TRIB expects to fulfill the TrinScreen HIV order across the fourth quarter of 2025 and first quarter of 2026. The company’s manufacturing adjustments will ensure timely delivery and operational efficiency. This order is anticipated to strengthen revenue and profitability for upcoming quarters.
Strong Financial Performance and Revenue Growth
TRIB reported Q3 2025 revenues of $14.3 million, up 32% from Q2 2025. Growth was driven by TrinScreen HIV and Uni-Gold HIV test sales as demand rebounded. Hemoglobin product sales also increased significantly, reflecting improved market conditions.
Gross profit rose to $6.5 million in Q3 2025, aided by a higher gross margin of 45.2%. The improvement reflects structural changes under the company’s Comprehensive Transformation Plan. Adjusted EBITDA reached $0.5 million compared to negative $2.1 million in the previous quarter.
TRIB issued updated financial presentations on its website, detailing operational performance and revenue drivers. The data highlights successful implementation of new manufacturing processes. The reports also emphasize consistent progress in strategic initiatives supporting growth.
Operational Restructuring and Strategic Outlook
TRIB completed key regulatory approvals, including WHO authorization for outsourcing HIV test production. These approvals allow the company to expand manufacturing efficiently under its Comprehensive Transformation Plan. The initiatives aim to enhance operational efficiency and profitability.
The company plans to prioritize operational milestones in Q4 2025 and Q1 2026. Achieving these objectives is expected to improve Adjusted EBITDA further. TRIB continues to strengthen its position in the global infectious disease diagnostics market.
TRIB stock movement reflects confidence in its strategic plans and product demand. The TrinScreen HIV order signals a strong recovery in global HIV testing initiatives. The company is well-positioned for sustainable growth in the healthcare diagnostics sector.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
